Richard N. Kitsis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Richard N. Kitsis has a total of 251 co-authors. Here are the top co-authors by number of shared publications:
- Evripidis Gavathiotis
Department of Biochemistry, Albert Einstein College of Medicine, Bronx, USA
6 shared publications Klitos Konstantinidis
Department of Medicine, Albert Einstein College of Medicine, Bronx, NY
6 shared publicationsRyan Pekson
Department of Medicine, Albert Einstein College of Medicine, Bronx, USA
5 shared publicationsYun Chen
Department of Medicine, Albert Einstein College of Medicine, Bronx, USA
5 shared publicationsJaehoon Lee
Department of Medicine, Albert Einstein College of Medicine, Bronx, USA
4 shared publicationsJoshua L. Axelrod
Department of Medicine, Albert Einstein College of Medicine, Bronx, USA
4 shared publications
Latest Publications
- 27 October 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (11) , 1271-1288
Manipulation of ER–mitochondria interactions with mitofusin modulators reduces cardiac damage during myocardial infarction in mice
Mitofusin (MFN) 1 and MFN2 are large outer mitochondrial membrane GTPases. Dimerization of MFNs on adjacent mitochondria mediates mitochondrial fusion. MFN2, but not MFN1, also resides at the endoplasmic reticulum (ER)/sarcoplasmic reticulum (SR) membrane, and dimerization of MFNs on ER/SR and mitochondria tethers the two organelles. Here we report that cell-permeable peptides that perturb MFN conformations regulate myocardial infarct size by impacting ER/SR–mitochondria interactions and Ca2+ transfer independently of changes in mitochondrial fusion. MFN activators increase ER/SR–mitochondria proximity, promote ER/SR to mitochondria Ca2+ transfer and exacerbate infarct size in mice, with effects dependent on MFN2, but not MFN1, and on mitochondrial calcium uniporter, which transports Ca2+ into the mitochondrial matrix. Conversely, although ER/SR–mitochondria proximity is not affected, MFN inhibitors reduce mitochondrial Ca2+ transfer and infarct size, even when their administration is delayed until reperfusion. These findings demonstrate the feasibility of acutely modulating ER/SR–mitochondria interactions and Ca2+ dynamics and suggest that pharmacological MFN inhibition may provide a new therapeutic strategy to limit cardiac damage during reperfused myocardial infarction.
- 27 October 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (11) , 1271-1288
Manipulation of ER–mitochondria interactions with mitofusin modulators reduces cardiac damage during myocardial infarction in mice
Mitofusin (MFN) 1 and MFN2 are large outer mitochondrial membrane GTPases. Dimerization of MFNs on adjacent mitochondria mediates mitochondrial fusion. MFN2, but not MFN1, also resides at the endoplasmic reticulum (ER)/sarcoplasmic reticulum (SR) membrane, and dimerization of MFNs on ER/SR and mitochondria tethers the two organelles. Here we report that cell-permeable peptides that perturb MFN conformations regulate myocardial infarct size by impacting ER/SR–mitochondria interactions and Ca2+ transfer independently of changes in mitochondrial fusion. MFN activators increase ER/SR–mitochondria proximity, promote ER/SR to mitochondria Ca2+ transfer and exacerbate infarct size in mice, with effects dependent on MFN2, but not MFN1, and on mitochondrial calcium uniporter, which transports Ca2+ into the mitochondrial matrix. Conversely, although ER/SR–mitochondria proximity is not affected, MFN inhibitors reduce mitochondrial Ca2+ transfer and infarct size, even when their administration is delayed until reperfusion. These findings demonstrate the feasibility of acutely modulating ER/SR–mitochondria interactions and Ca2+ dynamics and suggest that pharmacological MFN inhibition may provide a new therapeutic strategy to limit cardiac damage during reperfused myocardial infarction.
- 29 August 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (6) , 924-929
Regulated Cell Death in Myocardial Infarction
- 29 August 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (6) , 924-929
Regulated Cell Death in Myocardial Infarction
- 19 August 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (7) , 486-488
Reformulation of the Necroptosis Pathway in Reperfused Myocardial Infarction
- 19 August 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (7) , 486-488
Reformulation of the Necroptosis Pathway in Reperfused Myocardial Infarction
- 26 November 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (22) , 1812-1814
Extracellular Role for the Intracellular Cell Death Mediator RIPK3 in Myocardial Infarction
- 26 November 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (22) , 1812-1814
Extracellular Role for the Intracellular Cell Death Mediator RIPK3 in Myocardial Infarction
- Top Cited Papers
- 13 August 2024
- Published by Elsevier in Molecular Cell
- Vol. 84 (16) , 3098-3114.e6
OPA1 promotes ferroptosis by augmenting mitochondrial ROS and suppressing an integrated stress response
- 13 August 2024
- Published by Elsevier in Molecular Cell
- Vol. 84 (16) , 3098-3114.e6
Top Cited PapersOPA1 promotes ferroptosis by augmenting mitochondrial ROS and suppressing an integrated stress response
- Open Access
- 13 December 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (51)
The mitochondrial ATP synthase is a negative regulator of the mitochondrial permeability transition pore
The mitochondrial permeability transition pore (mPTP) is a channel in the inner mitochondrial membrane whose sustained opening in response to elevated mitochondrial matrix Ca 2+ concentrations triggers necrotic cell death. The molecular identity of mPTP is unknown. One proposed candidate is the mitochondrial ATP synthase, whose canonical function is to generate most ATP in multicellular organisms. Here, we present mitochondrial, cellular, and in vivo evidence that, rather than serving as mPTP, the mitochondrial ATP synthase inhibits this pore. Our studies confirm previous work showing persistence of mPTP in HAP1 cell lines lacking an assembled mitochondrial ATP synthase. Unexpectedly, however, we observe that Ca 2+ -induced pore opening is markedly sensitized by loss of the mitochondrial ATP synthase. Further, mPTP opening in cells lacking the mitochondrial ATP synthase is desensitized by pharmacological inhibition and genetic depletion of the mitochondrial cis-trans prolyl isomerase cyclophilin D as in wild-type cells, indicating that cyclophilin D can modulate mPTP through substrates other than subunits in the assembled mitochondrial ATP synthase. Mitoplast patch clamping studies showed that mPTP channel conductance was unaffected by loss of the mitochondrial ATP synthase but still blocked by cyclophilin D inhibition. Cardiac mitochondria from mice whose heart muscle cells we engineered deficient in the mitochondrial ATP synthase also demonstrate sensitization of Ca 2+ -induced mPTP opening and desensitization by cyclophilin D inhibition. Further, these mice exhibit strikingly larger myocardial infarctions when challenged with ischemia/reperfusion in vivo. We conclude that the mitochondrial ATP synthase does not function as mPTP and instead negatively regulates this pore.
- 13 December 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (51)
Open AccessThe mitochondrial ATP synthase is a negative regulator of the mitochondrial permeability transition pore
The mitochondrial permeability transition pore (mPTP) is a channel in the inner mitochondrial membrane whose sustained opening in response to elevated mitochondrial matrix Ca 2+ concentrations triggers necrotic cell death. The molecular identity of mPTP is unknown. One proposed candidate is the mitochondrial ATP synthase, whose canonical function is to generate most ATP in multicellular organisms. Here, we present mitochondrial, cellular, and in vivo evidence that, rather than serving as mPTP, the mitochondrial ATP synthase inhibits this pore. Our studies confirm previous work showing persistence of mPTP in HAP1 cell lines lacking an assembled mitochondrial ATP synthase. Unexpectedly, however, we observe that Ca 2+ -induced pore opening is markedly sensitized by loss of the mitochondrial ATP synthase. Further, mPTP opening in cells lacking the mitochondrial ATP synthase is desensitized by pharmacological inhibition and genetic depletion of the mitochondrial cis-trans prolyl isomerase cyclophilin D as in wild-type cells, indicating that cyclophilin D can modulate mPTP through substrates other than subunits in the assembled mitochondrial ATP synthase. Mitoplast patch clamping studies showed that mPTP channel conductance was unaffected by loss of the mitochondrial ATP synthase but still blocked by cyclophilin D inhibition. Cardiac mitochondria from mice whose heart muscle cells we engineered deficient in the mitochondrial ATP synthase also demonstrate sensitization of Ca 2+ -induced mPTP opening and desensitization by cyclophilin D inhibition. Further, these mice exhibit strikingly larger myocardial infarctions when challenged with ischemia/reperfusion in vivo. We conclude that the mitochondrial ATP synthase does not function as mPTP and instead negatively regulates this pore.
- 12 September 2023
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 184, 1-12
BAK contributes critically to necrosis and infarct generation during reperfused myocardial infarction
- 12 September 2023
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 184, 1-12
BAK contributes critically to necrosis and infarct generation during reperfused myocardial infarction
- 13 July 2023
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 182, 73-74
Introduction to review series: Regulated necrosis programs in heart disease
- 13 July 2023
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 182, 73-74
Introduction to review series: Regulated necrosis programs in heart disease
- 5 August 2022
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 131 (4) , 364-366
Cardiac Myosin Heavy Chain Reporter Mice to Study Heart Development and Disease
- 5 August 2022
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 131 (4) , 364-366
Cardiac Myosin Heavy Chain Reporter Mice to Study Heart Development and Disease